Notably, GNbAC1, a humanized IgG4 monoclonal antibody that specifically targets ERVWE1, has already been used in a year-long phase 2b clinical trial for multiple sclerosis [128]. The gene discussed is ERVW-1; the disease is multiple sclerosis.